mTOR, translation initiation and cancer
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Control of mRNA translation plays a fundamental role in many aspects of cell metabolism. It constitutes a critical step in the control of gene expression, and consequently cell growth, proliferation and differentiation. Translation is regulated in response to nutrient availability, hormones, mitogenic and growth factor stimulation and is coupled with cell cycle progression and cell growth. Signaling by the PI3K/Akt/mTOR pathway profoundly affects mRNA translation through phosphorylation of downstream targets such as 4E-BP and S6K. Inhibitors of this pathway and thus cap-dependent translation are emerging as promising therapeutic options for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such a shift has been associated with proliferation in tumorigenesis, and has been linked to the translational control of RPs (Mamane et al., 2006; Ruggero and Sonenberg, 2005).”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Mamane et al., 2006
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 5×
“…factors and hormones) with aminoacid availability and intracellular energy status to control translation rates and additional metabolic processes (Hay and Sonenberg, 2004) (Figure 2). mTOR has received considerable attention, as rapamycin (Rapamune) is a specific inhibitor of mTOR activity (for…”
BackgroundInfluentialSelf-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“An important downstream target of this signaling pathway is cap-dependent mRNA translation (Hay and Sonenberg, 2004; Hennessy et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the…”
BackgroundeIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationRegulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationHolz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,239 · cited 1×
“…Heat and Acid-Stable protein regulated by Insulin) and 4E-BP2, were identified in a screen using radiolabelled recombinant eIF4E protein to probe a human placenta expression library (Pause et al., 1994) and by sequencing the complementary DNA (cDNA) clone for PHAS-I (Hu et al., 1994).”
BackgroundSelf-citationMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093 · cited 1×
“Enhancement of the eIF4E/4E-BP interaction, through the expression of a constitutively active 4E-BP mutant (all phosphorylation sites mutated to Ala), leads to a decrease in cell size and inhibition of cell cycle progression in a manner that mimics rapamycin treatment (Fingar et al., 2002, 2004).”
BackgroundKim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961 · cited 1×
“…et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the 4E-BPs (Gingras et al., 2001; Jacinto and Hall, 2003; Kim et al., 2003; Ruggero and Pandolfi, 2003; Kim and Sabatini, 2004).”
BackgroundMalignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956 · cited 1×
“…binding (Gingras et al., 1999b). eIF4G recruits the 40S small ribosomal subunit to the mRNA through the ribosomeassociated eIF3. eIF4E eIF4E was the first translation factor shown to cause malignant transformation when overexpressed in cul- tured rodent cells (Lazaris-Karatzas et al., 1990).”
BackgroundSelf-citationSurvival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951 · cited 1×
“Furthermore, two groups independently demonstrated that eIF4E promotes lymphomagenesis in cooperation with Myc in transgenic mice (Ruggero et al., 2004; Wendel et al., 2004).”
Background
Cited by
Ingolia, N. T., Lareau, L. F., & Weissman, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.10.002 · Cited by 2,187
“Polysome-profiling experiments have suggested a global increase in cellular translation during early ESC differentiation, and we see a modest upregulation of RPs in our early time point (Sampath et al., 2008).”
BackgroundInfluentialAutosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Shimobayashi, M., & Hall, M. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3757 · Cited by 1,053
Alao, J. P. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-24 · Cited by 871
“Mammalian target of rapamycin (mTOR) is a target of the phosphatidylinositol 3-Kinase (PI3K)/protein kinase B (PKB/Akt) pathway (reviewed in [121-126]) and plays a major role in coupling mitogenic stimuli to cell cycle progression.”
Mammalian target of rapamycin: a central node of complex signaling cascades.
Dobashi, Y., Watanabe, Y., Miwa, C., Suzuki, S., & Koyama, S. (2011) · PubMed Central · Cited by 752
PI3K/Akt: getting it right matters
Franke, T. F. (2008) · Oncogene · doi:10.1038/onc.2008.313 · Cited by 695
“As a result, ribosomal protein kinase p70S6k and eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) are phosphorylated by mTOR (Inoki et al., 2002; Tee et al., 2002), thus leading to increased translation of existing mRNA transcripts (for review, see Mamane et al., 2006).”
BackgroundThe regulation and function of Class III PI3Ks: novel roles for Vps34
Backer, J. M. (2008) · Biochemical Journal · doi:10.1042/bj20071427 · Cited by 659
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Moerke, N. J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M. Y., Fahmy, A., Gross, J. D., Degterev, A., Yuan, J., Chorev, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.046 · Cited by 572
“The kinase mTOR is the major upstream regulator of 4E-BPs: stimuli such as nutrients and growth factors induce 4EBP phosphorylation and increased cellular eIF4F through signaling pathways that activate mTOR (Averous and Proud, 2006; Mamane et al., 2006; Petroulakis et al., 2006; Tee and Blenis, 2005; Wullschleger et a…”
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
Furic, L., Rong, L., Larsson, O., Koumakpayi, I. H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005320107 · Cited by 519
“via the phosphorylation of the suppressor 4E-BPs by mammalian target of rapamycin complex 1 (mTORC1) (1, 14).”
BackgroundSelf-citationFacchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q., et al. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.120 · Cited by 509
“In the presence of growth-promoting signals such as nutrients and growth factors, mTOR controls growth by upregulation of protein synthesis (Mamane et al, 2006; Wullschleger et al, 2006).”
BackgroundSignalling to translation: How signal transduction pathways control the protein synthetic machinery
Proud, C. G. (2007) · Biochemical Journal · doi:10.1042/bj20070024 · Cited by 520
The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 511
“stimulating cap-dependent translation (15, 27).”
A Dual Program for Translation Regulation in Cellular Proliferation and Differentiation
Gingold, H., Tehler, D., Christoffersen, N. R., Nielsen, M. M., Asmar, F., Kooistra, S. M., Christophersen, N. S., Christensen, L. L., Borre, M., Sørensen, K. D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.011 · Cited by 495
“Originally, the interest in translation was mainly focused on initiation (Mamane et al., 2006; Sonenberg and Hinnebusch, 2009), yet, more recently, attention toward elongation has increased (Hsieh et al.”
BackgroundEukaryotic Initiation Factor 2 Phosphorylation and Translational Control in Metabolism
Baird, T. D., & Wek, R. C. (2012) · Advances in Nutrition · doi:10.3945/an.112.002113 · Cited by 469
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
“The mTOR kinase also controls angiogenic pathways via hypoxia-inducible factor-1 and vascular endothelial growth factor and via endothelial and smooth muscle cell proliferation.(1,2) mTOR substrates, activating signaling pathways, and mTOR itself have been shown to be dysregulated in a variety of human malignancies, m…”
BackgroundDissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Self-citationmTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling
Julien, L.-A., Carriere, A., Moreau, J., & Roux, P. P. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-09 · Cited by 435
“thus stimulates protein synthesis and cellular growth (50, 60).”
BackgroundCao, W., Manicassamy, S., Tang, H., Kasturi, S. P., Pirani, A., Murthy, N., & Pulendran, B. (2008) · Nature Immunology · doi:10.1038/ni.1645 · Cited by 398
“10–12,18).”
Cap and cap‐binding proteins in the control of gene expression
Topisirovic, I., Svitkin, Y. V., Sonenberg, N., & Shatkin, A. J. (2011) · WIREs RNA · doi:10.1002/wrna.52 · Cited by 401
Self-citationmTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R., & Tee, A. R. (2015) · Oncogene · doi:10.1038/onc.2014.164 · Cited by 391
Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis
Ebright, R. Y., Lee, S., Wittner, B. S., Niederhoffer, K. L., Nicholson, B. T., Bardia, A., Truesdell, S., Wiley, D. F., Wesley, B., Li, S., et al. (2020) · Science · doi:10.1126/science.aay0939 · Cited by 365
FoxOs Inhibit mTORC1 and Activate Akt by Inducing the Expression of Sestrin3 and Rictor
Chen, C.-C., Jeon, S.-M., Bhaskar, P. T., Nogueira, V., Sundararajan, D., Tonic, I., Park, Y., & Hay, N. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.03.008 · Cited by 368
Global analysis of cellular protein translation by pulsed SILAC
Schwanhäusser, B., Gossen, M., Dittmar, G., & Selbach, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800275 · Cited by 356
“Given the current interest in translational regulation as a control mechanism in gene expression, pulsed SILAC should be applicable to a wide range of biological questions [27, 28].”
Pharmacological PKA Inhibition: All May Not Be What It Seems
Murray, A. J. (2008) · Science Signaling · doi:10.1126/scisignal.122re4 · Cited by 327
“S6K1 is a downstream target of mammalian target of rapamycin (mTOR) and has been implicated in processes as diverse as insulin signaling (33), regulation of cell size (34), and oncogenesis (35).”
BackgroundTranslation from unconventional 5′ start sites drives tumour initiation
Sendoel, A., Dunn, J. G., Rodriguez, E. H., Naik, S., Gomez, N. C., Hurwitz, B., Levorse, J., Dill, B. D., Schramek, D., Molina, H., et al. (2017) · Nature · doi:10.1038/nature21036 · Cited by 331
Role of Dietary Proteins and Amino Acids in the Pathogenesis of Insulin Resistance
Tremblay, F., Lavigne, C., Jacques, H., & Marette, A. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.25.050304.092545 · Cited by 319
Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination
Narayanan, S. P., Flores, A. I., Wang, F., & Macklin, W. B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0232-09.2009 · Cited by 325
“Activation of mTOR signaling in Aktoverexpressing oligodendrocytes Another major Akt substrate, mTOR, is known to regulate protein translation, with a central role in cell growth regulation (Mamane et al., 2006; Dann et al., 2007).”
BackgroundMalakar, P., Shilo, A., Mogilevsky, A., Stein, I., Pikarsky, E., Nevo, Y., Benyamini, H., Elgavish, S., Zong, X., Prasanth, K. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1508 · Cited by 317
“The Ras-MAPK and PI3K-mTOR pathways are deregulated in many cancers, contributing to the establishment and maintenance of the transformed phenotype (52,53).”
BackgroundMcCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., Suzuki, K., Iida, H., Sakamoto, Y., Yoneda, K., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0186 · Cited by 311
Autophagy as a therapeutic target in cancer
Chen, N., & Karantza, V. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14622 · Cited by 303
mTOR signaling in cellular and organismal energetics
Albert, V., & Hall, M. N. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.12.001 · Cited by 304
“4E-BPs and S6K are the main regulators of protein synthesis downstream of mTORC1 [6,11] (Figure 1a).”
BackgroundZakikhani, M., Dowling, R. J. O., Sonenberg, N., & Pollak, M. N. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0081 · Cited by 294
“If in certain cancer cells normal adiponectin levels contribute to baseline AMPK activation and thus constrain mTOR activation, the low adiponectin levels associated with obesity may be associated with higher levels of mTOR signaling and downstream events that contribute to the malignant phenotype (25).”
BackgroundSelf-citationPathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
“AKT can also activate the mammalian target of rapamycin (mTOR), which controls cap-dependent translation, cell growth, and survival (recently reviewed in [131]).”
BackgroundmTORC 1 and mTORC 2 as regulators of cell metabolism in immunity
Linke, M., Fritsch, S. D., Sukhbaatar, N., Hengstschläger, M., & Weichhart, T. (2017) · FEBS Letters · doi:10.1002/1873-3468.12711 · Cited by 274
4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications
Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J., & Ramón y Cajal, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 270
Phospholipase signalling networks in cancer
Park, J. B., Lee, C. S., Jang, J.-H., Ghim, J., Kim, Y.-J., You, S., Hwang, D., Suh, P.-G., & Ryu, S. H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3379 · Cited by 276
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
Carriere, A., Romeo, Y., Acosta-Jaquez, H. A., Moreau, J., Bonneil, E., Thibault, P., Fingar, D. C., & Roux, P. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.159046 · Cited by 268
Abdelmohsen, K., Kuwano, Y., Kim, H. H., & Gorospe, M. (2008) · bchm · doi:10.1515/bc.2008.022 · Cited by 258
“The ROS-induced PI3K-Akt pathway enhances cell growth and proliferation, at least in part, by activating mTOR (Mamane et al., 2006; Schieke and Finkel, 2006).”
BackgroundSelective autophagy degrades DICER and AGO2 and regulates miRNA activity
Gibbings, D., Mostowy, S., Jay, F., Schwab, Y., Cossart, P., & Voinnet, O. (2012) · Nature Cell Biology · doi:10.1038/ncb2611 · Cited by 252
Martelli, A. M., Evangelisti, C., Chiarini, F., & McCubrey, J. A. (2010) · Oncotarget · doi:10.18632/oncotarget.114 · Cited by 248
“eIF4E is a key component for translation of 5’ capped mRNAs, which include transcripts encoding growth promoting molecules, such as c-Myc, cyclin D1, cyclin-dependent kinase 2, retinoblastoma protein, p27Kip1, vascular endothelial growth factor (VEGF), and signal activator and transducer of transcription 3 (STAT3) [34…”
BackgroundRole of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Jiang, B.-H., & Liu, L.-Z. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.03.001 · Cited by 243
Regulation of muscle growth in neonates
Davis, T. A., & Fiorotto, M. L. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32831cef9f · Cited by 236
Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation
Gandin, V., Miluzio, A., Barbieri, A. M., Beugnet, A., Kiyokawa, H., Marchisio, P. C., & Biffo, S. (2008) · Nature · doi:10.1038/nature07267 · Cited by 236
The Role of Cdc25A in the Regulation of Cell Proliferation and Apoptosis
Shen, T., & Huang, S. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800617678 · Cited by 225
Buchkovich, N. J., Yu, Y., Zampieri, C. A., & Alwine, J. C. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1855 · Cited by 229
mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1
Kantidakis, T., Ramsbottom, B. A., Birch, J. L., Dowding, S. N., & White, R. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005188107 · Cited by 218
“The target of rapamycin (TOR) pathway performs this role in yeast and higher organisms (3, 4).”
BackgroundDeng, L., Zhou, J.-F., Sellers, R. S., Li, J.-F., Nguyen, A. V., Wang, Y., Orlofsky, A., Liu, Q., Hume, D. A., Pollard, J. W., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090622 · Cited by 228
Rizzieri, D. A., Feldman, E., DiPersio, J. F., Gabrail, N., Stock, W., Strair, R., Rivera, V. M., Albitar, M., Bedrosian, C. L., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 222
“The categories were chosen primarily based on the scientific implication of the PI3K/Akt/mTOR pathway and the potential of mTOR inhibition to affect angiogenesis (2).”
BackgroundmTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer
de la Cruz López, K. G., Toledo Guzmán, M. E., Sánchez, E. O., & García Carrancá, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01373 · Cited by 223
“Protein translation can be simplified into four stages: initiation, elongation, termination, and ribosomes recycling, however the critical regulation point occurs in the step of mRNA translation initiation, this step is regulated by several key signaling pathways, including PI3K/Akt/mTORC1 that in fact are over expres…”
BackgroundEvidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate
Gan, X., Wang, J., Su, B., & Wu, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.195016 · Cited by 209
“The mTORC1 activity is sensitive to inhibition by rapamycin, which regulates diverse cellular processes, including protein synthesis, ribosome biogenesis, transcription and autophagy, some of which are regulated through its direct substrates S6 kinases (S6K) and the eIF-4E binding protein 1 [13-16].”
BackgroundTargeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Zhou, Q., Lui, V. W., & Yeo, W. (2011) · Future Oncology · doi:10.2217/fon.11.95 · Cited by 210
“It is known that both of the proteins regulate the translation of several important proliferative and angiogenic factors, such as c-myc, cyclinD1, HIF1a and VEGF [71,72].”
BackgroundInfluentialIs there a role for carbohydrate restriction in the treatment and prevention of cancer?
Klement, R. J., & Kämmerer, U. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-75 · Cited by 206
“Akt also activates mTOR, a key regulator of cell growth and proliferation that integrates signaling from insulin and growth factors, amino acid availability, cellular energy status and oxygen levels [49,50].”
BackgroundSircar, K., Yoshimoto, M., Monzon, F. A., Koumakpayi, I. H., Katz, R. L., Khanna, A., Alvarez, K., Chen, G., Darnel, A. D., Aprikian, A. G., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2559 · Cited by 208
“Akt activates downstream mTOR, which promotes phosphorylation of S6, leading to mRNA translation [6,7].”
BackgroundThe Critical Role of IL-15–PI3K–mTOR Pathway in Natural Killer Cell Effector Functions
Nandagopal, N., Ali, A. K., Komal, A. K., & Lee, S.-H. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00187 · Cited by 196
“Activation of mTOR complex 1 (mTORC1) leads to the phosphorylation of several downstream targets such as 70-S6 kinase (S6K); and this kinase activity of mTORC1 is blocked by rapamycin treatment (24).”
BackgroundMethodInfluentialHwang-Verslues, W. W., Chang, P.-H., Wei, P.-C., Yang, C.-Y., Huang, C.-K., Kuo, W.-H., Shew, J.-Y., Chang, K.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2011) · Oncogene · doi:10.1038/onc.2010.618 · Cited by 200
“Loss of S6K phosphorylation during hypoxia serves as an indicator of inhibited mTOR signaling (Mamane et al., 2006).”
BackgroundGlutamine metabolism regulates autophagy-dependent mTORC1 reactivation during amino acid starvation
Tan, H. W. S., Sim, A. Y. L., & Long, Y. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00369-y · Cited by 192
Spangle, J. M., & Münger, K. (2010) · Journal of Virology · doi:10.1128/jvi.00974-10 · Cited by 189
Amato, R. J., Jac, J., Giessinger, S., Saxena, S., & Willis, J. P. (2009) · Cancer · doi:10.1002/cncr.24280 · Cited by 201
“Mammalian target of rapamycin (mTOR) is an intracellular kinase that regulates cellular responses to nutrients, energy, and exogenous growth factors.(10,11) When energy and nutrient resources are replete, when growth factors are stimulating the cells, or when defects in the cells upstream of mTOR provide aberrant stim…”
BackgroundTamburini, J., Green, A. S., Bardet, V., Chapuis, N., Park, S., Willems, L., Uzunov, M., Ifrah, N., Dreyfus, F., Lacombe, C., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184515 · Cited by 190
TOR regulation of AGC kinases in yeast and mammals
Jacinto, E., & Lorberg, A. (2008) · Biochemical Journal · doi:10.1042/bj20071518 · Cited by 205
Green, A. S., Chapuis, N., Trovati Maciel, T., Willems, L., Lambert, M., Arnoult, C., Boyer, O., Bardet, V., Park, S., Foretz, M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269837 · Cited by 199
A comparative analysis of the cell biology of senescence and aging
Hwang, E. S., Yoon, G., & Kang, H. T. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0034-2 · Cited by 190
Showkat, M., Beigh, M. A., & Andrabi, K. I. (2014) · Molecular Biology International · doi:10.1155/2014/686984 · Cited by 189
Malakar, P., Stein, I., Saragovi, A., Winkler, R., Stern-Ginossar, N., Berger, M., Pikarsky, E., & Karni, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1432 · Cited by 188
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194
“Nonetheless, rapamycin strongly affects cell proliferation, cell growth and angiogenesis (Averous and Proud, 2006; Easton and Houghton, 2006; Mamane et al., 2006; Sabatini, 2006).”
Yu, S., Shen, G., Khor, T. O., Kim, J.-H., & Kong, A.-N. T. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2400 · Cited by 189
“[6]thymidine and L-[3,4,5]leucine were obtained from Perkin-Elmer.”
MethodOrdered Organelle Degradation during Starvation-induced Autophagy
Kristensen, A. R., Schandorff, S., Høyer-Hansen, M., Nielsen, M. O., Jaüaüttelaü, M., Dengjel, J., & Andersen, J. S. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800184-mcp200 · Cited by 165
“vation leads to a cell cycle arrest (33), we assumed that”
BackgroundMetformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185
Metabolism and mitochondria in polycystic kidney disease research and therapy
Padovano, V., Podrini, C., Boletta, A., & Caplan, M. J. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0051-1 · Cited by 181
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20637 · Cited by 177
“translation [35].”
The Biology Behind mTOR Inhibition in Sarcoma
Wan, X., & Helman, L. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-1007 · Cited by 180
The role of mTOR in memory CD8+ T‐cell differentiation
Araki, K., Youngblood, B., & Ahmed, R. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00898.x · Cited by 178
“One of the best-studied areas of mTORC1 research is its translational control induced by phosphorylating 4E-BP1 and S6K1 (43) (Fig.”
BackgroundAmiel, E., Everts, B., Freitas, T. C., King, I. L., Curtis, J. D., Pearce, E. L., & Pearce, E. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103741 · Cited by 175
Yu, X., & Long, Y. C. (2016) · Scientific Reports · doi:10.1038/srep30033 · Cited by 170
Gan, X., Wang, J., Wang, C., Sommer, E., Kozasa, T., Srinivasula, S., Alessi, D., Offermanns, S., Simon, M. I., & Wu, D. (2012) · Nature Cell Biology · doi:10.1038/ncb2507 · Cited by 163
The MHC class I peptide repertoire is molded by the transcriptome
Fortier, M.-H., Caron, E., Hardy, M.-P., Voisin, G., Lemieux, S., Perreault, C., & Thibault, P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071985 · Cited by 171
Wang, F.-Z., Weber, F., Croce, C., Liu, C.-G., Liao, X., & Pellett, P. E. (2008) · Journal of Virology · doi:10.1128/jvi.00961-08 · Cited by 166
“miR-100 and miR-101 have predicted targets on the mTOR pathway, which is important in regulating the translation of capped mRNAs, cell size, cell growth, cell cycle, cell survival, and cytoskeletal organization (37) (Fig.”
Ye, Q., Cai, W., Zheng, Y., Evers, B. M., & She, Q.-B. (2014) · Oncogene · doi:10.1038/onc.2013.122 · Cited by 163
Essential Role of TGF-β Signaling in Glucose-Induced Cell Hypertrophy
Wu, L., & Derynck, R. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.05.010 · Cited by 167
“Cell growth is defined as increase in cell mass, often associated with increased protein synthesis (Mamane et al., 2006).”
Fujishita, T., Aoki, K., Lane, H. A., Aoki, M., & Taketo, M. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800041105 · Cited by 161
“To investigate the activation status of the mTOR signaling pathway in intestinal polyps induced by Wnt signaling activation, we examined phosphorylation of S6, which is catalyzed by S6 kinase in an mTOR-dependent manner (10), in the intestinal polyps and the normal ileum in Apc 716 mice.”
MethodChapuis, N., Tamburini, J., Green, A. S., Vignon, C., Bardet, V., Neyret, A., Pannetier, M., Willems, L., Park, S., Macone, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1102 · Cited by 175
“Copyright © 2010 American Association for Cancer Research (13).”
BackgroundThe role of mTOR in the management of solid tumors: An overview
Strimpakos, A. S., Karapanagiotou, E. M., Saif, M. W., & Syrigos, K. N. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.09.006 · Cited by 160
Azpurua, J., Ke, Z., Chen, I. X., Zhang, Q., Ermolenko, D. N., Zhang, Z. D., Gorbunova, V., & Seluanov, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313473110 · Cited by 154
“Int J Biochem Cell Biol 36(12):2519–2530.”
Kong, D., Wang, Z., Sarkar, S. H., Li, Y., Banerjee, S., Saliganan, A., Kim, H.-R. C., Cher, M. L., & Sarkar, F. H. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1076 · Cited by 155
Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer
Sathe, A., & Nawroth, R. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7234-0_23 · Cited by 160
The Late Endosome is Essential for mTORC1 Signaling
Flinn, R. J., Yan, Y., Goswami, S., Parker, P. J., & Backer, J. M. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-09-0756 · Cited by 158
“mTORC1 activity is stimulated by growth factors such as insulin and by nutrients such as amino acids and glucose (Harris and Lawrence, 2003; Jaeschke et al., 2004; Sarbassov et al., 2005; Tee and Blenis, 2005; Avruch et al., 2006; Mamane et al., 2006).”
BackgroundWang, H., Zhang, Q., Wen, Q. J., Zheng, Y., Lazarovici, P., Jiang, H., Lin, J., & Zheng, W. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.010 · Cited by 165
Yu, G., Wang, J., Chen, Y., Wang, X., Pan, J., Li, G., Jia, Z., Li, Q., Yao, J. C., & Xie, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2138 · Cited by 156
ER stress affects processing of MHC class I-associated peptides
Granados, D. P., Tanguay, P.-L., Hardy, M.-P., Caron, É., de Verteuil, D., Meloche, S., & Perreault, C. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-10 · Cited by 146
“Infection and neoplastic transformation increase protein translation and thereby the folding demand on the ER [9,10].”
BackgroundIL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells
Ali, A. K., Nandagopal, N., & Lee, S.-H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00355 · Cited by 142
“To translate the importance of PI3K–mTOR pathway for NK cell functions during virus infection, we treated mice with rapamycin to block mTOR kinase activity downstream of PI3K (30, 81).”
BackgroundThe La and related RNA‐binding proteins (LARPs): structures, functions, and evolving perspectives
Maraia, R. J., Mattijssen, S., Cruz‐Gallardo, I., & Conte, M. R. (2017) · WIREs RNA · doi:10.1002/wrna.1430 · Cited by 139
“Positive regulation of eIF4E activity, as with stimulation of mTOR activity after treatment of cells with insulin involves its release from the eIF4E-binding proteins (4E-BPs), which are repressors of translation initiation.(189,190)”
BackgroundYoshizawa, A., Fukuoka, J., Shimizu, S., Shilo, K., Franks, T. J., Hewitt, S. M., Fujii, T., Cordon-Cardo, C., Jen, J., & Travis, W. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0986 · Cited by 145
“The phosphorylation of 4EBP-1 by mTOR results in the release of a cap-binding protein eukaryotic translation initiation factor complex 4E (eIF4E), which is held inactive when bound to the hypophosphorylated 4EBP-1 complex (14, 15, 22).”
BackgroundCancer-specific mutations in phosphatidylinositol 3-kinase
Vogt, P. K., Kang, S., Elsliger, M., & Gymnopoulos, M. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.05.005 · Cited by 157
Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer
Krisenko, M. O., & Geahlen, R. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.10.022 · Cited by 158
Li, R., Pourpak, A., & Morris, S. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9002395 · Cited by 146
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis
Mukherjee, R., Vanaja, K. G., Boyer, J. A., Gadal, S., Solomon, H., Chandarlapaty, S., Levchenko, A., & Rosen, N. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.033 · Cited by 135
“mTOR is a regulator of cap-dependent translation (Mamane et al., 2006), so we employed L-azidohomoalanine (AHA), an azide-containing methionine analog, to determine whether it regulates PTEN expression in this way (Tom Dieck et al.”
MethodEJCs at the Heart of Translational Control
Hir, H. L., & Séraphin, B. (2008) · Cell · doi:10.1016/j.cell.2008.04.002 · Cited by 136
“TOR signals to several cellular machineries, including the translation initiation apparatus via the S6 kinase (S6K) (Mamane et al., 2006).”
Background
Metadata
- Authors
- Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N.
- Affiliations
- McGill University (CA)
- Corresponding author
- Sonenberg, N
- ORCID
- Sonenberg, N
- Venue
- Oncogene
- Published
- 2006-10-16
- Volume
- 25
- Issue
- 48
- Pages
- 6416-6422
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2165848665
- Cited by
- 607
- References
- 79
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 28 · 2022: 14 · 2021: 7 · 2020: 23 · 2019: 16 · 2018: 32 · 2017: 26 · 2016: 28 · 2015: 41 · 2014: 41 · 2013: 40 · 2012: 41
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mTOR, mRNA translation, translation initiation, PI3K/AKT/mTOR pathway, 4E-BP, S6K, cap-dependent translation, cancer therapy, nutrient signaling, cell growth
- MeSH terms
- Animals, Gene Expression Regulation, Humans, Mammals, Models, Genetic, Neoplasms, Peptide Chain Initiation, Translational, Protein Kinases, Signal Transduction, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.